Grifols, S.A. (NASDAQ:GRFS) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Grifols, S.A. has received a consensus rating of "Moderate Buy" from five research firms, with three hold recommendations, one buy, and one strong buy.
• The company's stock price target has been raised to $10.30 by analysts, following updates from firms such as JPMorgan and Wall Street Zen.
• Grifols is set to pay a dividend of $0.1404 per share on August 20th, with a dividend payout ratio of 11.97%.

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $10.30.

A number of equities analysts have commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their price objective on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th. Zacks Research upgraded Grifols to a "hold" rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th.

Grifols Price Performance

Shares of Grifols stock opened at $10.74 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The business's 50 day simple moving average is $9.61 and its two-hundred day simple moving average is $8.23. The stock has a market capitalization of $7.38 billion, a P/E ratio of 9.18, a price-to-earnings-growth ratio of 0.36 and a beta of 0.56. Grifols has a one year low of $6.19 and a one year high of $11.14.

Grifols Announces Dividend

The firm also recently disclosed a -- dividend, which will be paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th will be given a dividend of $0.1404 per share. The ex-dividend date of this dividend is Tuesday, August 12th. Grifols's dividend payout ratio (DPR) is 11.97%.

Institutional Trading of Grifols

A number of hedge funds have recently bought and sold shares of GRFS. Versant Capital Management Inc purchased a new stake in Grifols in the first quarter worth about $28,000. Tower Research Capital LLC TRC increased its position in Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after buying an additional 6,335 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock worth $74,000 after buying an additional 4,604 shares in the last quarter. First Trust Advisors LP purchased a new stake in Grifols in the fourth quarter worth about $75,000. Finally, Ballentine Partners LLC purchased a new stake in Grifols in the first quarter worth about $77,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.